For millions of people with treatment-resistant depression — a condition that fails to respond to standard antidepressants — the options have long been grim. But two landmark Phase 3 clinical trials have now changed the landscape dramatically.
Compass Pathways announced in early 2026 that its synthetic psilocybin therapy, COMP360, successfully met its primary endpoint in a second pivotal Phase 3 trial (COMP006), following an earlier success in COMP005. Both trials enrolled patients with treatment-resistant depression — defined as failing at least two prior antidepressant treatments — and both showed statistically significant reductions in depressive symptoms at six weeks.
The results are striking. Durability data from COMP005 showed that clinically meaningful improvements were sustained for at least 26 weeks after just one or two doses. Final durability data from COMP006 is expected in early Q3 2026 and will be the final piece needed before an FDA filing.
Compass has already secured FDA Breakthrough Therapy designation for COMP360, which puts it on a priority review track. The company plans to request a rolling submission — submitting and having portions reviewed as they're completed — and anticipates a full New Drug Application by Q4 2026. A first-ever FDA approval of a psychedelic medicine could follow in late 2026 or 2027.
The treatment model is unlike any conventional antidepressant. Rather than taking a pill daily, patients receive one or two guided sessions with COMP360, combined with psychological support. The therapy appears to reset patterns of depression rather than managing ongoing symptoms. Early long-term follow-up data from an earlier study, published separately, found that two-thirds of participants remained in complete remission five years after treatment.
Treatment-resistant depression affects an estimated 100 million people globally. For many of them, the possibility of durable remission from a handful of guided sessions — rather than a lifetime of daily medication — represents a fundamental shift in what recovery could look like.
